Introduction
============

Esophageal cancer (EC) is the sixth common cause of cancer death worldwide and has become a major health concern, especially in Asia.[@b1-ott-9-4289] There are two primary forms of EC, for example, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most prevalent type in eastern countries, while esophageal adenocarcinoma often occurs in the West. Since the exact diagnosis is rarely made prior to advanced clinical stages, the overall 5-year survival rate of patients with ESCC remains extremely low, despite wide application of operation and chemo-radiotherapy.[@b2-ott-9-4289]--[@b4-ott-9-4289] EC ranks fourth in morbidity and mortality in People's Republic of China, after lung cancer, gastric cancer, and liver cancer.[@b5-ott-9-4289] One of the main reasons for the low overall survival is the lack of appropriate molecular biomarkers for the early detection or prognosis of EC.

Melanoma antigen gene family A (MAGEA) family comprises 12 subtypes from MAGEA1 to MAGEA12.[@b6-ott-9-4289] Reports have shown that *MAGEA* genes are upregulated in different types of cancer, such as lymphocytic leukemia, lung cancer, ovarian cancer, melanoma, and other cancers.[@b7-ott-9-4289],[@b8-ott-9-4289] *MAGEA4* is a gene of *MAGEA*. Upregulation of *MAGEA4* has been found in several types of tumors, for example, oral squamous cell carcinoma,[@b9-ott-9-4289] non-small-cell lung cancer,[@b10-ott-9-4289] pancreatic cancer,[@b11-ott-9-4289] and breast cancer.[@b12-ott-9-4289] In the present study, we examined the expression of *MAGEA4* in ESCC tissues and investigated the significance and prognostic value of *MAGEA* expression in patients with ESCC.

Materials and methods
=====================

Patients and tissue samples
---------------------------

A total of 120 ESCC and corresponding samples were obtained from patients who underwent surgery during 2001--2008 at Nanjing Hospital affiliated with the Nanjing Medical University, People's Republic of China. None of the patients received radiotherapy or chemotherapy before the operation. All specimens were immediately stored at −80°C in a refrigerator until use. Each patient was followed up from 2 months to 5 years. The study was approved by the Ethics Committee of Nanjing First Hospital, Nanjing Medical University. Written informed consent was obtained from all patients before they participated in the research.

RNA isolation and quantitative real-time polymerase chain reaction
------------------------------------------------------------------

Total RNA was isolated from cancerous/noncancerous tissues with TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA). Complementary DNAs were obtained with the Prime-Script™ RT-PCR kit (Takara, Dalian, People's Republic of China). *MAGEA4* messenger RNA (mRNA) expression was measured by quantitative real-time polymerase chain reaction (qRT-PCR) with the following primer sequences: forward, 5′-CCACTACCATCAGCTTCACTTGC-3′ and reverse, 5′-AGGCAACCCAATGAGGGTTCCAGC-3′. The MAGEA4 mRNA levels were normalized to GAPDH using the sequences: forward, 5′-GTCAACGGATTTGGTCTGTATT-3′ and reverse, 5′-AGTCTTCTGGGTGGCAGTGAT-3′. qRT-PCR reactions were performed with ABI7500 System and SYBR Green PCR Master Mix (Thermo Fisher Scientific).

Statistical analysis
--------------------

For ESCC tissues and the corresponding nontumor ones, the fold change of target gene is indicated by 2^−∆CT^. All data were tested by Student's *t*-test, chi-square test, and analysis of variance, as appropriate. Overall survival curves were plotted by the method of Kaplan--Meier. Multivariate data were analyzed by Cox proportional hazards model. All statistical analyses were performed with Statistical Package for the Social Sciences Version 19 (IBM Corporation, Armonk, NY, USA). For all results, a *P*-value of \<0.05 was considered statistically significant.

Results
=======

Expression of MAGEA4 mRNA in patients with ESCC and normal tissues
------------------------------------------------------------------

The *MAGEA4* expression levels in cancerous tissues and corresponding noncancerous tissues from 120 patients with ESCC were measured by qRT-PCR. Relative gene expression determinations were made with 2^−∆CT^ method. *MAGEA4* expression of tumor tissue was significantly higher than that of nontumor tissues ([Figure 1](#f1-ott-9-4289){ref-type="fig"}).

Clinical significance of MAGEA4 mRNA in patients with ESCC
----------------------------------------------------------

The association between *MAGEA4* mRNA and clinicopathological features of 120 primary ESCC and nontumor samples was analyzed. As shown in [Table 1](#t1-ott-9-4289){ref-type="table"}, overexpression of *MAGEA4* mRNA level was not aberrantly associated with age, sex, and differentiation in patients with ESCC. However, overexpression of *MAGEA4* mRNA level was negatively associated with clinical stage and lymph node metastasis. The expression of *MAGEA4* in patients with ESCC with I--IIA stage disease was higher than that in patients with IIB--IV stage disease. Patients with ESCC with lymph node metastasis showed lower *MAGEA4* levels compared to those without lymph node metastasis.

Upregulation of MAGEA4 in early stage of ESCC is linked to poor survival
------------------------------------------------------------------------

As the frequency of *MAGEA4* overexpression was higher in early stages (I--IIA) than that in advanced stages (IIB--IV) ([Table 1](#t1-ott-9-4289){ref-type="table"}), the association of *MAGEA4* overexpression with overall survival rate in patients with ESCC was studied subsequently. Kaplan--Meier analysis was used to examine the prognostic value of *MAGEA4* mRNA for overall survival of patients with ESCC. Patients with ESCC with overexpression of *MAGEA4* mRNA were significantly linked to poor overall survival (log rank =5.565, *P*=0.018) ([Figure 2](#f2-ott-9-4289){ref-type="fig"}). Univariate analysis showed that tumor node metastasis (TNM) stage (*P*\<0.05), *MAGEA4* overexpression (*P*=0.032), and lymph node metastasis (*P*\<0.05) were independent prognostic factors for the 120 informative ESCC samples ([Table 2](#t2-ott-9-4289){ref-type="table"}).

Discussion
==========

A lack of efficient ESCC therapy makes it urgent to identify specific biomarkers as potential therapeutic targets of patients with ESCC. The method of qRT-PCR has made it possible to detect molecular biomarkers for the assessment of micrometastasis.[@b13-ott-9-4289] *MAGEA4* is a member of the cancer/testis antigen family and does not express in normal tissues except in the placenta or testis. The expression of cancer testis antigen is most specific for cancer. *MAGEA4* expresses in several carcinomas, for example, head and neck cancer (53%), lung cancer (51%), bladder cancer (33%), and cancer of esophagus (63%).[@b14-ott-9-4289] *MAGEA4* is expected to be the optimal candidate for being a therapeutic target of ESCC.

To our knowledge, our study is the first one to detect *MAGEA4* mRNA expression in tissues of patients with ESCC. Chaux et al[@b14-ott-9-4289] found that *MAGEA4* is a member of the cancer/testis antigen family and does not express in normal tissues except in the placenta or testis. Sharma et al[@b15-ott-9-4289] examined the expression of seven gene products including *MAGEA4* in 94 bladder tumor samples and observed that MAGEA4 had the highest incidence of expression compared to other types of genes. As a result, *MAGEA4* is expected to be the optimal candidate for being a therapeutic target of ESCC.

In the present study, we examined the expression of *MAGEA4* genes in ESCC tissues and their corresponding nontumor esophageal tissues. Our results demonstrated that in 120 pairs of tumor and nontumor esophageal tissues, *MAGEA4* expression of tumor tissues was significantly higher than that of nontumor tissues. We analyzed its relationship with the clinical data and found that *MAGEA4* mRNA level was not linked to age, sex, and differentiation in ESCC. However, overexpression of *MAGEA4* mRNA level was negatively associated with clinical stage and lymph node metastasis. Clinical stage and lymph node metastasis are two important indicators of tumor malignancy of patients with ESCC. Patients with ESCC with overexpressed *MAGEA4* are aberrantly associated with poorer overall survival, compared to patients not showing overexpression of *MAGEA4* in tumors. Univariate Cox proportional hazard regression analysis showed that *MAGEA4* mRNA was not an independent factor for overall survival. Sex, TNM stage, and lymph node metastasis are all dangerous factors for overall survival of patients with ESCC.

In the present study, we examined the expression of *MAGEA4* genes in ESCC tissues and their corresponding nontumor esophageal tissues. Our results demonstrated that in 120 pairs of tumor and nontumor esophageal tissues, *MAGEA4* expression of tumor tissue was significantly higher than that of nontumor tissues. This trend is consistent with other reports.[@b14-ott-9-4289] ESCC patients with higher *MAGEA4* mRNA expression are more prone to lymph node metastasis. Kaplan--Meier analysis showed that patients with ESCC with overexpression of *MAGEA4* mRNA were significantly linked to poor overall survival. [Figure 2](#f2-ott-9-4289){ref-type="fig"} showed the prognostic value of *MAGEA4* mRNA for overall survival of patients with ESCC, indicating that the higher the expression, the worse the prognosis.

Patients carrying ESCC with overexpressed *MAGEA4* are aberrantly associated with poorer overall survival, compared to patients not showing overexpression of *MAGEA4* in tumors. In our research, we did a comprehensive analysis of several factors by multivariate Cox proportional hazard regression analysis and found that only three factors were meaningful. They were TNM stage, lymph node metastasis, and *MAGEA4* mRNA expression. Sex, age, and differentiation may not influence the overall survival of patients with ESCC independently.

Conclusion
==========

In summary, our data demonstrated that *MAGEA4* mRNA was commonly upregulated in patients with ESCC. Overexpression of *MAGEA4* mRNA in ESCC tumor was significantly associated with poor overall survival of patients with ESCC. Therefore, *MAGEA4* mRNA could be used as a prognostic marker for predicting the overall survival of patients with ESCC after surgery.
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![*MAGEA4* expression in tumor tissues and normal tissues in 120 ESCC patients.\
**Abbreviations:** ESCC, esophageal squamous cell carcinoma; *MAGEA4*, melanoma antigen gene family A 4.](ott-9-4289Fig1){#f1-ott-9-4289}

![Prognostic value of *MAGEA4* mRNA for overall survival of patients with ESCC in Kaplan--Meier analysis.\
**Abbreviations:** ESCC, esophageal squamous cell carcinoma; *MAGEA4*, melanoma antigen gene family A 4; mRNA, messenger RNA.](ott-9-4289Fig2){#f2-ott-9-4289}

###### 

Clinicopathological characteristics and expression of *MAGEA4*

  Clinicopathological characteristics   Number (n)   *MAGEA4* mRNA (n)   *P*-value    
  ------------------------------------- ------------ ------------------- ------------ --------------------------------------------------
  Sex                                                13                  107          0.071
   Male                                 98           13 (13.3)           85 (86.7)    
   Female                               22           0 (0.0)             22 (100.0)   
  Age                                                                                 0.204
   ≥62 years                            57           4 (7.0)             53 (93.0)    
   \<62 years                           63           9 (14.3)            54 (85.7)    
  Histological type                                                                   0.362
   High-middle                          100          12 (12.0)           88 (88.0)    
   Low                                  20           1 (5.0)             19 (95.0)    
  TNM stage group                                                                     0.001[\*](#tfn1-ott-9-4289){ref-type="table-fn"}
   I--IIA                               85           9 (10.1)            76 (89.4)    
   IIB--IV                              35           4 (11.4)            31 (88.6)    
  Lymph node metastasis                                                               0.001[\*](#tfn1-ott-9-4289){ref-type="table-fn"}
   Yes                                  35           9 (25.7)            26 (74.3)    
   No                                   85           4 (4.7)             81 (95.3)    

**Note:**

*P*\<0.05.

**Abbreviations:** *MAGEA4*, melanoma antigen gene family A 4; TNM, tumor node metastasis; mRNA, messenger RNA.

###### 

Univariate and multivariate Cox analyses

  Variables                                   HR      95% CI         *P*-value
  ------------------------------------------- ------- -------------- --------------------------------------------------
  **Univariate Cox analysis**                                        
  Sex (male vs female)                        1.166   0.716--1.899   0.537
  TNM stage (I--IIA vs IIB--IV)               2.838   1.791--4.498   0.000[\*](#tfn3-ott-9-4289){ref-type="table-fn"}
  *MAGEA4* overexpression (without vs with)   2.165   1.068--4.388   0.032[\*](#tfn3-ott-9-4289){ref-type="table-fn"}
  Lymph node metastasis (without vs with)     2.838   1.791--4.498   0.000[\*](#tfn3-ott-9-4289){ref-type="table-fn"}
  **Multivariate Cox analysis**                                      
  Sex (male vs female)                        1.357   0.807--2.281   0.250
  Age (≥62 years vs \<62 years)               1.124   0.741--1.704   0.583
  TNM stage (I--IIA vs IIB--IV)               3.778   2.335--6.114   0.000[\*](#tfn3-ott-9-4289){ref-type="table-fn"}
  *MAGEA4* overexpression (without vs with)   3.385   1.634--7.014   0.001[\*](#tfn3-ott-9-4289){ref-type="table-fn"}
  Histological type (high-middle vs low)      0.923   0.548--1.554   0.763
  Lymph node metastasis (without vs with)     3.778   2.335--6.114   0.000[\*](#tfn3-ott-9-4289){ref-type="table-fn"}

**Note:**

*P*\<0.05.

**Abbreviations:** CI, confidence interval; HR, hazard ratio; *MAGEA4*, melanoma antigen gene family A 4; TNM, tumor node metastasis.
